About Kineta
Kineta is a Healthcare company based in Seattle (United States) founded in 2008, and was acquired by TuHURA Biosciences in February 2025. Immune-modulating therapeutics are developed for autoimmune and infectious diseases. Kineta has raised $152.31 million across 45 funding rounds from investors including HHS, TuHURA Biosciences and Cheongbo Industrial. The company has 12 employees. Kineta offers products and services including KVA12123 and CD27. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Adjuvant. Its legal entity is Kineta Inc. Its competitors include Emergent BioSolutions, Adjuvance Technologies and Eikonoklastes; 2 of its 3 listed competitors have raised funding.
Company details
Kineta is focused on developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases. Autoimmune disease pipeline includes dalazitide in clinical trial phase 1B for Lupus, Psoriasis, Psoriatic Arthritis, RA, MS, Vasculitis, IBD, Asthma, AD, Type 1 diabetes (T1D). Antiviral pipeline includes compounds of preclinical categories innate-immune antivirals, vaccine adjuvants and direct-acting antivirals all of which discovered using its proprietary aviid antiviral discovery platform. It also has a chronic pain candidate in preclinical stage for diabetic nephropathy and traumatic injury
- Headquarters Seattle, United States
- Employees 12
- Stage Acquired
- SectorsHealthcare
- Website kinetabio.com
- Social LinkedIn X Facebook
- Acquired by TuHURA Biosciences (Feb 2025)
- Legal Name Kineta Inc.
- Annual Revenue$442 K (USD)-77as on Feb 28, 2023
- Net Profit-$17.13 M (USD)-22as on Feb 28, 2024
- EBITDA-$13.53 M (USD)14as on Feb 28, 2024
- Total Equity Funding$152.31M (USD)
in 45 rounds
- Latest Funding Round$17.4M (USD), Series D
Jun 2022
- InvestorsHHS
& 6 more
- Employee Count12
- Acquired byTuHURA Biosciences
(Feb 2025)
Products & Services of Kineta
Kineta offers a comprehensive portfolio of products and services, including KVA12123 and CD27.
Blocks VISTA protein to enhance immune response against cancer.
Targets CD27 for improved cancer immune system activation.
Funding Insights of Kineta
Kineta has successfully raised a total of $152.31M across 45 strategic funding rounds. The most recent funding activity was a Series D round of $17.4 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152.31M
- Total Rounds 45
- Last Round Series D — $17.4M
- First Round $3.33M
(Sep 2008)
- Investors Count 6
Latest 10 of 45 funding rounds of Kineta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $17.4M | Series D | – | – | – |
| Feb 2022 | $2.4M | Series D | – | – | – |
| Jul 2021 | $1.18M | Series D | – | – | – |
| Jun 2021 | $16.34M | Series D | – | Cheongbo Industrial | – |
| Nov 2020 | Debt – Conventional | – | – | – | |
| Nov 2020 | $20.28M | Series D | – | – | – |
| Jun 2020 | $100,001 | Series C | – | – | – |
| May 2020 | $4.75M | Series C | – | – | – |
| Oct 2019 | $2.95M | Series C | – | – | – |
| Sep 2019 | $2.5M | Series C | – | – | – |
7 investors in total: 7 institutional.
Investors in Kineta
Kineta has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, TuHURA Biosciences and Cheongbo Industrial.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| k4northwest.com | ||||
Major auto components are manufactured and supplied to aftermarket. | 1959 | cheongbo.co.kr | Incheon, South Korea | |
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
| niaid.nih.gov | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| iacoccafoundation.org | ||||
Developer of immunotherapies for the treatment of cancer | 1996 | tuhurabio.com | Tampa, United States |
Investor details for Kineta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kineta
10 people are tracked at Kineta (3 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Yulia Ovechkina | Associate Director, Immuno-oncology | Leadership |
Kurt Lustig | Director, Translational Development | Leadership |
Charles Magness | Co-founder | Leadership |
Michael A. Curran | Advisor | Board & advisors |
Myriam Chalabi | Advisor | Board & advisors |
Evan Y. Yu | Advisor | Board & advisors |
Marion R. Foote | Director | Board & advisors |
Lisa Coussens | Advisor | Board & advisors |
Patricia LoRusso | Advisor | Board & advisors |
Thu le | Controller | Team |
Complete people profiles for Kineta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kineta
4 dated milestones of Kineta across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Kineta is founded.
- Funding First funding round of $3.3M.
- Funding Latest funding round, Series D, of $17.4M.
- Exit Acquired by TuHURA Biosciences.
Competitors of Kineta
Kineta has 3 listed competitors in our database, 2 of them funded. They include Emergent BioSolutions, Adjuvance Technologies and Eikonoklastes.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| emergentbiosolutions.com | 1998 | Gaithersburg, United States | 1 | Vaccines for viral infections are developed by the company. | ||
| adjuvancetechnologies.com | 2009 | New York, United States | $13.37M | 20 | Vaccine adjuvants are designed and manufactured for medical applications. | |
| eikonoklastes.com | 2019 | Columbus, United States | $20.76M | 3 | Tissue factor targeting therapeutics for cancer treatment are developed. |
Detailed competitors of Kineta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kineta
Websites that share an audience with Kineta (kinetabio.com).
Websites whose visitors overlap most with Kineta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| senseibio.com | 100% | 4.5K | #4,696,262 | View details | |
| hummingbirdbioscience.com | 90% | 5K | #1,579,101 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Kineta (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kineta
Complete news archive for Kineta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kineta
Kineta was founded in 2008.
Kineta is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Kineta is a funded company, having raised a total of $152.31M across 45 funding rounds to date. The company's 1st funding round was a Series C of $2.5M, raised on Sep 2008.
Kineta has 12 employees.
Annual revenue of Kineta is $442K as on Feb 28, 2023.
Kineta is focused on developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases. Autoimmune disease pipeline includes dalazitide in clinical trial phase 1B for Lupus, Psoriasis, Psoriatic Arthritis, RA, MS, Vasculitis, IBD, Asthma, AD, Type 1 diabetes (T1D). Antiviral pipeline includes compounds of preclinical categories innate-immune antivirals, vaccine adjuvants and direct-acting antivirals all of which discovered using its proprietary aviid antiviral discovery platform. It also has a chronic pain candidate in preclinical stage for diabetic nephropathy and traumatic injury.
Kineta's top competitors include Adjuvance Technologies, Emergent BioSolutions and Eikonoklastes.
Kineta offers KVA12123 and CD27.
Kineta has 7 investors. Key investors include HHS, TuHURA Biosciences, Cheongbo Industrial, Wellcome, and NIAID.
Kineta operates through Kineta Inc..
Yes. Kineta was acquired by TuHURA Biosciences in February 2025.